VIYASH

Concall Schedule Concall Date: November 14, 2026 Concall Time: 11:00 AM IST

- Viyash Scientific Limited approved the allotment of 2,28,408 equity shares of face value Rs. 2/- each on November 2, 2026. - Allotment includes 1,93,000 shares at Rs. 86 each under Sequent ESOP 2020 and 35,408 shares at Rs. 101 each under Viyash ESOP 2026. - Paid-up equity share capital increased to Rs. 88,39,83,916/- comprising 44,19,91,958 equity shares.

- Viyash Scientific Limited incorporated Alivira Vietnam Company Limited as a step-down wholly owned subsidiary on October 30, 2026. - The new entity is a wholly owned subsidiary of Alivira Animal Health Limited, India. - It operates in the pharmaceuticals sector, focusing on importation, registration, marketing, and distribution of animal health products, APIs, and phytogenic solutions in Vietnam. - Total cash consideration/investment is up to USD 400,000.

- Appointment of Dr. Mallikharjuna Rao Nagineni as Senior Vice President - Human Resources and Senior Management Personnel, effective October 20, 2026. - Cessation of Mr. Prasad Lad as Senior Management Personnel effective October 20, 2026, due to his forthcoming retirement.

- Viyash Scientific Limited has approved the allotment of 1,35,880 equity shares of face value Rs. 2/- each pursuant to ESOP exercises. - 79,000 shares allotted at an exercise price of Rs. 86 per share under Sequent ESOP 2020. - 56,880 shares allotted at an exercise price of Rs. 101 per share under Viyash ESOP 2026. - Total paid-up equity share capital increased from Rs. 88,32,55,340 to Rs. 88,35,27,100.

- Allotment of 1,35,880 equity shares of face value ₹2/- each pursuant to ESOP exercise. - 79,000 shares allotted at ₹86 per share under Sequent ESOP 2020. - 56,880 shares allotted at ₹101 per share under Viyash ESOP 2026. - Paid-up equity capital increased to ₹88,35,27,100 comprising 44,17,63,550 equity shares.

- Viyash Scientific Limited announced that its step-down wholly owned subsidiary, Alivira Animal Health Limited, Ireland, has completed the acquisition of 100% share capital of BioForLife Italia S.r.l., Milan, Italy on October 1, 2026. - Base purchase consideration paid on closing is EUR 15.0 million along with the agreed reference net financial position. - Balance purchase consideration of EUR 1.976 million is payable as deferred consideration subject to adjustments. - Representatives of Alivira Animal Health Limited have been appointed to the Board of BFL Italy.

- Trading window for Designated Persons and their relatives closed from October 01, 2026. - Closure remains in effect until 48 hours after declaration of Q2 FY27 unaudited financial results.